Curative gene therapies for rare diseases

被引:13
|
作者
Maldonado, Rocio [1 ]
Jalil, Sami [1 ]
Wartiovaara, Kirmo [1 ,2 ]
机构
[1] Univ Helsinki, Stem Cells & Metab Res Program, Helsinki, Finland
[2] Helsinki Univ Hosp, Clin Genet, Helsinki, Finland
基金
芬兰科学院;
关键词
CRISPR-Cas9; Gene therapy; Genetic engineering; FETAL-HEMOGLOBIN; VISUAL RECOVERY; LYMPHOCYTES; CELLS; TRIAL; REPLACEMENT; DEFICIENCY; MECHANISMS; DELIVERY;
D O I
10.1007/s12687-020-00480-6
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Diseases caused by alterations in the DNA can be overcome by providing the cells or tissues with a functional copy of the mutated gene. The most common form of gene therapy implies adding an extra genetic unit into the cell. However, new genome engineering techniques also allow the modification or correction of the existing allele, providing new possibilities, especially for dominant diseases. Gene therapies have been tested for 30 years in thousands of clinical trials, but presently, we have only three authorised gene therapy products for the treatment of inherited diseases in European Union. Here, we describe the gene therapy alternatives already on the market in the European Union and expand the scope to some clinical trials. Additionally, we discuss the ethical and regulatory issues raised by the development of these new kinds of therapies.
引用
收藏
页码:267 / 276
页数:10
相关论文
共 50 条
  • [11] The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases
    P. J. Brooks
    Timothy M. Miller
    Frédéric Revah
    Junghae Suh
    Bradley R. Garrison
    Lawrence C. Starke
    Timothy K. MacLachlan
    Edward G. Neilan
    Gopa Raychaudhuri
    Sadik H. Kassim
    Jean Dehdashti
    Joni L. Rutter
    Nature Reviews Drug Discovery, 2024, 23 : 157 - 158
  • [12] The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases
    Brooks, P. J.
    Miller, Timothy M.
    Revah, Frederic
    Suh, Junghae
    Garrison, Bradley R.
    Starke, Lawrence C.
    MacLachlan, Timothy K.
    Neilan, Edward G.
    Raychaudhuri, Gopa
    Kassim, Sadik H.
    Dehdashti, Jean
    Rutter, Joni L.
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (03) : 157 - 158
  • [13] OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES: GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE
    Dabbous, M.
    Francois, C.
    Chachoua, L.
    Hanna, E.
    Toumi, M.
    VALUE IN HEALTH, 2019, 22 : S737 - S738
  • [14] Infrastructuring precision medicine: Making gene therapies for rare diseases workable in practice
    Wadmann, Sarah
    Johansen, Anna Brueckner
    Born, Alfred Peter
    Kessel, Line
    SOCIAL SCIENCE & MEDICINE, 2024, 351
  • [15] Incentivizing Therapies for Rare Diseases Reply
    Thomas, Shailin
    Caplan, Arthur
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (05): : 465 - 465
  • [16] Gene Therapies for Polyglutamine Diseases
    Matos, Carlos A.
    Carmona, Vitor
    Vijayakumar, Udaya-Geetha
    Lopes, Sara
    Albuquerque, Patricia
    Conceicao, Mariana
    Nobre, Rui Jorge
    Nobrega, Clevio
    de Almeida, Luis Pereira
    POLYGLUTAMINE DISORDERS, 2018, 1049 : 395 - 438
  • [17] Gene therapies for neuromuscular diseases
    Saffari, Afshin
    Weiler, Markus
    Hoffmann, Georg Friedrich
    Ziegler, Andreas
    NERVENARZT, 2019, 90 (08): : 809 - 816
  • [18] ‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases
    Katie Kingwell
    Nature Reviews Drug Discovery, 2021, 20 : 886 - 887
  • [20] Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry
    Mavilio, F.
    GENE THERAPY, 2017, 24 (09) : 590 - 592